Durvalumab Combinations Push the Response Envelope in Unresectable NSCLC

(MedPage Today) -- Patients with unresectable stage III non-small cell lung cancer (NSCLC) had a higher response rate and better progression-free survival when novel targeted agents were added to treatment with durvalumab (Imfinzi), a phase II...